デフォルト表紙
市場調査レポート
商品コード
1536168

ブドウ球菌感染症治療薬の世界市場

Staphylococcal Infection Drugs

出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
適宜更新あり
ブドウ球菌感染症治療薬の世界市場
出版日: 2024年08月16日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

ブドウ球菌感染症治療薬の世界市場は2030年までに68億米ドルに達する見込み

2023年に60億米ドルと推定されるブドウ球菌感染症治療薬の世界市場は、分析期間2023-2030年にCAGR 1.8%で成長し、2030年には68億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるβ-ラクタム薬は、CAGR 2.6%を記録し、分析期間終了時には22億米ドルに達すると予測されます。ペプチド医薬品セグメントの成長率は、分析期間中CAGR 1.8%と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 3.5%で成長すると予測

米国のブドウ球菌感染症治療薬市場は2023年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは3.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と1.7%と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

主な動向と促進要因

様々なブドウ球菌に起因するブドウ球菌感染症は、軽度の皮膚炎症から敗血症、心内膜炎、肺炎のような生命を脅かす疾患まで、様々な臨床症状で現れます。これらの感染症の治療は、従来は抗生物質に頼ることが多かったが、MRSA（メチシリン耐性黄色ブドウ球菌）のような抗生物質耐性株の脅威の増大により、新たな治療アプローチの必要性が高まっています。現在の薬剤に対する耐性がエスカレートするにつれ、研究者たちは、ファージ療法、ワクチン開発、宿主免疫系調節戦略など、新規抗生物質や代替治療法の開発に追われています。

抗生物質耐性という課題に対応するため、製薬業界は、既知の耐性経路を回避できる革新的な薬剤メカニズムや併用療法にますます注力しています。さらに、ゲノムおよびプロテオミクス技術の進歩により、感染タイプをより正確に特定できるようになり、標的薬剤の開発や個別化治療アプローチが容易になりつつあります。このプレシジョン・メディシン・アプローチは、患者が特定の感染症プロファイルに基づいて最も効果的な薬剤を確実に投与されるようにすることで、治療成績を向上させると期待されています。

ブドウ球菌感染症治療薬の市場開拓は、薬剤耐性黄色ブドウ球菌感染症の発生率の増加、院内感染に対する認識とサーベイランスの強化、抗菌薬開発に対する規制当局のインセンティブ強化など、いくつかの要因によって推進されています。現在進行中の研究と投資は、新規細菌ターゲットの同定と既存の抗生物質の薬理学的特性の強化に重点を置いています。一方、世界の保健機関や政府機関は、資金援助や新薬の迅速な承認プロセスを通じて市場を強化し、効果的なブドウ球菌感染症治療に対する緊急のニーズに対応しています。

調査対象企業の例（注目の86社）

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26821

Global Staphylococcal Infection Drugs Market to Reach US$6.8 Billion by 2030

The global market for Staphylococcal Infection Drugs estimated at US$6.0 Billion in the year 2023, is expected to reach US$6.8 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2023-2030. Beta-Lactams Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Peptides Drugs segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 3.5% CAGR

The Staphylococcal Infection Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 3.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Key Trends and Drivers

Staphylococcal infections, attributable to various Staphylococcus bacteria strains, manifest in a range of clinical conditions from minor skin irritations to life-threatening diseases like sepsis, endocarditis, and pneumonia. The treatment of these infections traditionally relies heavily on antibiotics, but the growing threat of antibiotic-resistant strains such as MRSA (Methicillin-resistant Staphylococcus aureus) has intensified the need for new therapeutic approaches. As resistance to current drugs escalates, researchers are driven to develop novel antibiotics and alternative treatments, including phage therapy, vaccine development, and host immune system modulation strategies.

In response to the challenge of antibiotic resistance, the pharmaceutical industry is increasingly focusing on innovative drug mechanisms and combination therapies that can circumvent known resistance pathways. Additionally, advancements in genomic and proteomic technologies are enabling more precise identification of infection types, which facilitates targeted drug development and personalized treatment approaches. This precision medicine approach is expected to improve treatment outcomes by ensuring that patients receive the most effective drugs based on their specific infection profile.

The growth in the market for staphylococcal infection drugs is driven by several factors, including the increasing incidence of drug-resistant staph infections, heightened awareness and surveillance of hospital-acquired infections, and stronger regulatory incentives for developing antibacterial agents. Ongoing research and investment are focused on identifying novel bacterial targets and enhancing the pharmacological properties of existing antibiotics. Meanwhile, global health organizations and governmental bodies are bolstering the market through funding and fast-track approval processes for new drugs, addressing the urgent need for effective staphylococcal infection treatments.

Select Competitors (Total 86 Featured) -

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Staphylococcal Infection Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise of Antibiotic Resistance in Staphylococcal Infections
    • Development of Novel Antibacterial Agents
    • Advances in Rapid Bacterial Testing Technologies
    • Increased Incidence of Hospital-Acquired Infections
    • Growing Demand for Effective MRSA Infections Treatment
    • Impact of Global Health Initiatives on Antibiotic Development
    • Advances in Genomics and Pathogen Tracking
    • Public Awareness Campaigns and Education
    • Funding Increases for Antimicrobial Resistance Research
    • Adoption of Combination Therapy Strategies
    • Innovations in Vaccine Development for Staphylococcus Prevention
    • Economic Impact of Staph Infections on Healthcare Systems
    • Shift Towards Personalized Medicine and Tailored Therapies
    • Global Spread of Community-Acquired Staphylococcal Infections
    • Strategic Alliances Among Biopharma and Research Institutes
    • Patient-Centric Approaches in Drug Development
    • Challenges in Treating Multi-Drug Resistant Bacterial Strains
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Staphylococcal Infection Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Beta-Lactams Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Peptides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Quinolones Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Macrolides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Staphylococcal Infection Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Staphylococcal Infection Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION